[go: up one dir, main page]

WO1999064001A3 - Methods and compositions for increasing penetration of hiv protease inhibitors - Google Patents

Methods and compositions for increasing penetration of hiv protease inhibitors Download PDF

Info

Publication number
WO1999064001A3
WO1999064001A3 PCT/EP1999/003827 EP9903827W WO9964001A3 WO 1999064001 A3 WO1999064001 A3 WO 1999064001A3 EP 9903827 W EP9903827 W EP 9903827W WO 9964001 A3 WO9964001 A3 WO 9964001A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
hiv protease
protease inhibitors
increasing penetration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/003827
Other languages
French (fr)
Other versions
WO1999064001A2 (en
Inventor
Kenneth Russell Brouwer
Joseph William Polli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to JP2000553070A priority Critical patent/JP2002517443A/en
Priority to EP99927848A priority patent/EP1094814A2/en
Priority to AU45051/99A priority patent/AU4505199A/en
Publication of WO1999064001A2 publication Critical patent/WO1999064001A2/en
Publication of WO1999064001A3 publication Critical patent/WO1999064001A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to methods for increasing penetration of HIV protease-inhibiting compounds into tissues expressing P-glycoprotein.
PCT/EP1999/003827 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors Ceased WO1999064001A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000553070A JP2002517443A (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of HIV protease inhibitors
EP99927848A EP1094814A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors
AU45051/99A AU4505199A (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9812189.0 1998-06-05
GBGB9812189.0A GB9812189D0 (en) 1998-06-05 1998-06-05 Methods and compositions for increasing penetration of HIV protease inhibitors

Publications (2)

Publication Number Publication Date
WO1999064001A2 WO1999064001A2 (en) 1999-12-16
WO1999064001A3 true WO1999064001A3 (en) 2000-02-03

Family

ID=10833305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003827 Ceased WO1999064001A2 (en) 1998-06-05 1999-06-03 Methods and compositions for increasing penetration of hiv protease inhibitors

Country Status (5)

Country Link
EP (1) EP1094814A2 (en)
JP (1) JP2002517443A (en)
AU (1) AU4505199A (en)
GB (1) GB9812189D0 (en)
WO (1) WO1999064001A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304053B2 (en) 2000-10-17 2007-12-04 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance
US7476680B2 (en) 2000-10-17 2009-01-13 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
JP2000072749A (en) * 1998-08-24 2000-03-07 Mitsui Chemicals Inc Apoptosis inducer using quinoline derivative
JP2000290181A (en) * 1999-04-01 2000-10-17 Mitsui Chemicals Inc Intracerebral migration potentiator for encephalopathy therapeutic agent
CA2448834A1 (en) 2001-06-01 2002-12-12 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
JP2004532894A (en) 2001-06-13 2004-10-28 イーラン　ファーマスーティカルズ、インコーポレイテッド Amine diol for treating Alzheimer's disease
EP1404664A1 (en) 2001-07-10 2004-04-07 Elan Pharmaceuticals, Inc. Aminediols for the treatment of alzheimer's disease
CA2453444A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
BR0213139A (en) 2001-10-04 2004-08-10 Elan Pharm Inc Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
BR0214736A (en) 2001-12-06 2004-11-23 Elan Pharm Inc Compound and its pharmaceutically acceptable salts, pharmaceutical composition and method of treating humans or animals suffering from diseases or conditions
WO2004058686A1 (en) 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
CA2523232A1 (en) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease
WO2005087751A2 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005108391A1 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Amides as bace inhibitors
JP2008505930A (en) 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド Oxime derivative-substituted hydroxyethylamine aspartic protease inhibitors
WO2007047305A1 (en) 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US20140275139A1 (en) * 2013-03-12 2014-09-18 Hiv Diagnostics, Inc. Mdr method and products for treating hiv/aids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012132A1 (en) * 1991-01-11 1992-07-23 Laboratoires Glaxo S.A. Acridine derivatives
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1999012570A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012132A1 (en) * 1991-01-11 1992-07-23 Laboratoires Glaxo S.A. Acridine derivatives
WO1997035587A1 (en) * 1996-03-22 1997-10-02 Glaxo Group Limited Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
WO1999012570A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DREWE J., ET AL.: "HIV protease inhibitor Ritonavir: a more potent inhibitor of p_glycoprotein than the Cyclosporine analogue SDZ PSC 833", BIOCHEM. PHARMACOL., vol. 57, no. 10, 1999, pages 1147 - 1152, XP002114524 *
HYAFIL F ET AL: "IN VITRO AND IN VIVO REVERSAL OF MULTIDRUG RESISTANCE BY GF120918, AN ACRIDONECARBOXAMIDE DERIVATIVE", CANCER RESEARCH, vol. 53, no. 19, 1 October 1993 (1993-10-01), pages 4595 - 4602, XP000565696, ISSN: 0008-5472 *
KIM R.B. ET AL.: "The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors", J. CLINICAL INVESTIGATION, vol. 101, no. 2, 15 January 1998 (1998-01-15), pages 289 - 294, XP002114521 *
LEE C.G.L. ET AL.: "HIV-1 Protease inhibitors are substrates for the MDR1 multidrug transporter", BIOCHEMISTRY, vol. 37, no. 11, 1998, pages 3594 - 3601, XP002114522 *
WASHINGTON C.B. ET AL.: "Saquinavir is a hight affinity substrate for the multidrug transporter P-glycoprotein", CLIN. PHARMACOL. THERAP., vol. 61, no. 2, 1997, pages 193, XP002114523 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304053B2 (en) 2000-10-17 2007-12-04 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance
US7476680B2 (en) 2000-10-17 2009-01-13 H. Lee Moffitt Cancer Center & Research Institute, Inc. Substituted heterocyclic compounds for treating multidrug resistance

Also Published As

Publication number Publication date
JP2002517443A (en) 2002-06-18
AU4505199A (en) 1999-12-30
GB9812189D0 (en) 1998-08-05
WO1999064001A2 (en) 1999-12-16
EP1094814A2 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
WO1999064001A3 (en) Methods and compositions for increasing penetration of hiv protease inhibitors
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
WO2004032713A3 (en) Sealants for skin and other tissues
AU2001233081A1 (en) Composition for treatment of stress
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001219651A1 (en) Mulch composition and method
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
AU2002224079A1 (en) O/W emulsion composition and method of preparing the same
WO2004021990A3 (en) Compositions and kits for the removal of irritating compounds from bodily surfaces
AU2001239363A1 (en) Method for fighting against arthropods destructive of crops and composition therefor
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU2001243347A1 (en) Hydratable form of keratin for use as a soil amendment
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU2001274181A1 (en) Composition and method for biocide treatment of surfaces
AU2001224021A1 (en) Compositions for protecting plants and method of using the same
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2001264522A1 (en) Methods and compositions for the prevention of myopia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999927848

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09701949

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999927848

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999927848

Country of ref document: EP